Anish Bhatnagar is a distinguished leader in the biotechnology industry, currently serving as the Chief Executive Officer, President, Chief Operating Officer, and director at Soleno Therapeutics Inc. With a robust background in pharmaceuticals and life sciences, Anish has been instrumental in steering Soleno towards innovative therapeutic solutions. He joined Soleno in 2017, bringing with him a wealth of experience from previous roles where he demonstrated a knack for driving growth and operational excellence. Prior to Soleno, Anish held significant positions at companies such as Coherus BioSciences and Elan Pharmaceuticals, where he honed his skills in strategic planning and corporate development. At Soleno Therapeutics, Anish Bhatnagar has been pivotal in advancing the company's mission to develop novel treatments for rare diseases. Under his leadership, Soleno has made significant strides in its clinical programs, particularly with its lead candidate, DCCR, aimed at treating Prader-Willi syndrome. Anish's strategic vision has been crucial in navigating the complex landscape of rare disease therapeutics, ensuring that Soleno remains at the forefront of innovation and patient care. His role encompasses overseeing the company's operations, from research and development to commercialization, ensuring that all efforts are aligned with Soleno's overarching goals. Anish's achievements extend beyond his current role at Soleno. He has been recognized for his contributions to the biotech sector, receiving accolades for his leadership and commitment to advancing healthcare. His academic background, with degrees in chemical engineering and an MBA, has provided him with a solid foundation to tackle the multifaceted challenges of the industry. Anish's dedication to improving patient outcomes, combined with his strategic acumen, makes him a respected figure in the biotechnology community, driving Soleno Therapeutics towards a future of groundbreaking medical advancements.